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ABSTRACT
Telomerase adds telomeric DNA repeats to the
ends of linear chromosomal DNA. 3’-Azido-3’-
deoxythymidine 5’-triphosphate (AZTTP) is a
known telomerase inhibitor. To obtain more selec-
tive and potent inhibitors that can be employed
as tools for studying telomerase, we investigated
the telomerase-inhibitory effects of purine nucleo-
sides bearing a 3’-down azido group: 3’-azido-2’,
3’-dideoxyguanosine (AZddG) 5’-triphosphate
(AZddGTP), 3’-azido-2’,3’-dideoxy-6-thioguanosine
(AZddSG) 5’-triphosphate (AZddSGTP), 3’-azido-2’,
3’-dideoxyadenosine (AZddA) 5’-triphosphate
(AZddATP) and 3’-azido-2’,3’-dideoxy-2-aminoade-
nosine (AZddAA) 5’-triphosphate (AZddAATP). Of
these, AZddGTP showed the most potent inhibitory
activity against HeLa cell telomerase. AZddGTP was
significantly incorporated into the 3’-terminus of
DNA by partially purified telomerase. However,
AZddGTP did not exhibit significant inhibitory
activity against DNA polymerases a and d, suggest-
ing that AZddGTP is a selective inhibitor of
telomerase.
We also investigated whether long-term treatment
with these nucleosides could alter telomere length
and growth rates of human HL60 cells in culture.
Southern hybridization analysis of genomic DNA
prepared from cells cultured in the presence of
AZddG and AZddAA revealed reproducible telomere
shortening.
INTRODUCTION
Telomeres constitute the termini of eukaryotic chromo-
somes and incorporate linear chromosomal DNA ends
consisting of guanine-rich sequences and associated
protein components (1). Telomeres protect the ends of
each chromosome from degradation and loss of essential
genes, and allow the cell to distinguish between double-
strand breaks and natural chromosome ends. Functional
telomeres are essential for continued cell proliferation.
As a result of incomplete replication of lagging-strand
DNA synthesis and other end-processing events, telomeres
progressively shorten in all somatic cells with each cell
division (2). When telomeres become short, cells usually
undergo replicative senescence (3).
Telomerase is a cellular endogenous reverse transcrip-
tase (RT) believed to counteract this progressive short-
ening by directing the appropriate nucleotides onto the
telomeric ends of chromosomes, and play an important
role in the mechanism of tumor cell immortalization.
Telomerase is expressed in embryonic cells and adult male
germline cells (4), but is undetectable in normal somatic
cells with the exception of proliferating cells in tissues
undergoing renewal (5,6). In normal somatic cells,
progressive telomere shortening occurs, eventually leading
to greatly shortened telomeres and, consequently, limited
replicative capacity. In contrast to normal cells, tumor
cells generally have short telomeres and show no net loss
of average telomere length with successive cell divisions,
suggesting that telomere stability might be required
for cells to escape replicative senescence and proliferate
indeﬁnitely. In normal cells, telomerase activity appears
to be tightly controlled, but is reactivated in  90%
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therefore be a rate-limiting step for the continuing
proliferation of advanced cancers (7–11). Thus, a potential
therapeutic window exists in which cancer cells can be
eﬃciently targeted by telomerase inhibitors, while normal
telomerase-expressing cells, such as stem and germline
cells, remain unaﬀected as a result of their longer
telomeres and slower rates of cell division (12–14).
Numerous approaches for targeting telomeres and
telomerase activity have been studied (15). Telomerase is
a ribonucleoprotein in which the internal RNA serves as
a template for directing the telomere DNA sequence,
which in vertebrates is (TTAGGG)n (16). Therefore,
telomerase is classiﬁed as a RT (17,18). Classic methods
for aﬀecting enzymatic reverse transcription have proven
useful for identifying telomerase inhibitors. Strahl and
Blackburn analyzed whether known inhibitors of retro-
viral RTs, 20,30-dideoxyguanosine (ddG), 30-azido-20,
30-dideoxythymidine (AZT), 20,30-dideoxyadenosine
(ddA), 20,30-dideoxyinosine (ddI) and 20,30-didehydro-20,
30-dideoxythymidine (d4T), could perturb telomere length
and growth rates of two immortalized human cell lines.
Of these, only ddG caused reproducible telomere short-
ening, but had no observable eﬀect on cell growth rates
or morphology (19). Gomez et al. (20) reported that
treatment of HeLa cells with 800mM AZT caused short-
ening of the telomeric DNA. In this context, guanine
counterparts may be more potent inhibitors than other
base analogs, since telomerase catalyzes telomere DNA
elongation through addition of repeated guanine-rich
sequences, (e.g. TTAGGG). Additionally, the azido
group confers enhanced lipophilicity, which could be
expected to contribute signiﬁcantly to non-selective
transport across membranes (21). We have previously
demonstrated that 30-azido-20,30-dideoxyguanosine
(AZddG) 50-triphosphate (AZddGTP) (Figure 1) shows
more potent inhibition than 30-azido-30-deoxythymidine
50-triphosphate (AZTTP) (22). The present article
describes the inhibition of telomerase by purine counter-
parts of AZTTP and the mechanism of activity. We
report the eﬀects of AZddG, 30-azido-20,30-dideoxy-2-
aminoadenosine (AZddAA) and AZT on telomere
length and growth properties of the immortalized cell
line HL60, derived from human leukemia cells.
MATERIALS AND METHODS
Compounds
AZddG, 30-azido-20,30-dideoxy-6-thioguanosine
(AZddSG), AZT and AZddAA were synthesized accord-
ing to the procedures reported by Imazawa and Eckstein
(23) and Marchand et al. (24), with slight modiﬁcations.
Their triphosphate derivatives were also synthesized as
described, with slight modiﬁcations (25,26). The purity of
the triphosphate derivatives was conﬁrmed to be higher
than 95% as detected by UV absorption at the max of
each compound during HPLC analysis. HPLC analysis
was conducted using a TSK-GEL DEAE-2SW (TOSOH,
Tokyo, Japan) anion-exchange column as the solid
phase and 0.21M potassium phosphate buﬀer (pH 6.9)
containing 20% CH3CN as the mobile phase (1ml/min)
at room temperature. 9-b-D-Arabinofuranosylguanine
50-triphosphate (araGTP) was synthesized as reported
previously (27), and 30-azido-20,30-dideoxyadenosine
(AZddA) 50-triphosphate (AZddATP) and ddGTP were
purchased from TriLink BioTechnologies (San Diego,
CA, USA).
Cells and enzymes
HeLa cells and HL60 cells were obtained from the Riken
Gene Bank (Tsukuba, Japan). Recombinant HIV-1 RT
was purchased from Seikagaku Kogyo (Tokyo, Japan).
Calf DNA polymerase (pol) a (28) and human pol d were
provided by Dr M. Takemura of Tokyo University of
Science (Tokyo, Japan) and Dr K. Sakaguchi of Tokyo
University of Science (Chiba, Japan), respectively. Human
pol d was puriﬁed by the nuclear fractionation of human
peripheral blood cancer cells (Molt-4) using the second
subunit of pol d-conjugated to an aﬃnity column chro-
matography (29). Partially puriﬁed cherry salmon
telomerase was prepared from immature cherry salmon
testis as described previously (30).
Semi-quantitative telomerase assaybased onthe ‘stretch
PCR’ method
Standard telomerase assay. The reaction mixture (20ml)
for telomere DNA extension was comprised of 50mM
Tris–acetate/50mM potassium acetate (pH 8.5),
1mM MgCl2, 1mM dithiothreitol, 1mM TAG-U primer
(50-GTA AAA CGA CGG CCA GTT TGG GGT TGG
GGT TGG GGT TG-30), 10–200mM dGTP, 10–200mM
dTTP, 10–200mM dATP, inhibitors and a HeLa cell S-100
extract containing telomerase (1–2mg of protein).
The reaction mixture was incubated for 10min at 308C
Figure 1. Nucleoside and nucleotide analogs examined in this study.
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Isolation of product DNA, stretch PCR using CTA-R
reverse primer (50-CAG GAA ACA GCT ATG ACC
CCT AAC CCT AAC CCT AAC CCT-30), separation by
polyacrylamide gel electrophoresis, DNA detection by
staining with SYBR green I (Cambrex BioScience,
Rockland, ME, USA) and estimation of the product
concentrations were carried out as described previously
(31). A standard curve correlating the amount of enzyme
and PCR product was prepared, allowing the linearity
of the reaction to be conﬁrmed in each experiment.
Inhibition study and determination ofkinetic constants
Inhibition studies were performed by the addition of
various concentrations of nucleotide analogs to the
standard telomerase assay mixture. Inhibition mode and
kinetic constants were analyzed by Lineweaver–Burk
plot analyses.
Primerextension assay
The assay was performed essentially as described by
Tendian et al. (30,32). The reaction mixture (40ml) was
comprised of 50mM Tris–HOAc (pH 8.5), 50mM KOAc,
1mM MgCl2, 1mM dithiothreitol, 2mM (TTAGGG)3,
5mM[ a-
32P]dTTP (GE Healthcare Bio-Science,
Buckinghamshire, UK), 5mM dATP, 5 or 0mM dGTP,
several concentrations of dGTP analogs and 20mlo f
partially puriﬁed cherry salmon telomerase. Incubation
was performed for 1h at 258C. The reaction was termi-
nated by adding 0.5M EDTA (1ml) and 2mg/ml RNase A
(2ml) and incubating at 378C for 15min. The reaction mix
was further treated by adding 10% SDS (1ml) and 20mg/ml
proteinase K (1ml), then incubated at 378C for 15min.
Unincorporated radioactivity was removed by gel
ﬁltration using a MicroSpin G-25 (GE Healthcare
Bio-Science). DNA products were treated by phenol
extraction and isolated by ethanol precipitation, then
analyzed by electrophoresis on a 20% polyacrylamide–
7M urea sequencing gel. Autoradiography was carried out
by one-day exposure to imaging plates (Fuji Film, Tokyo,
Japan). Signals were detected using a ﬂuorescence image
analyzer FLA 3000 (Fuji Film).
Assayof DNA polymerases aand d
The reaction mixture (25ml) was comprised of 50mM
Tris–HCl (pH 7.5), 4mM MgCl2, 1mM dithiothreitol,
100mg/ml activated DNA, 20mM dGTP, 50mM each
dATP, dCTP and [
3H] dTTP (GE Healthcare Bio-
Science), 200mg/ml bovine serum albumin, 10% glycerol
and the enzyme preparation. Incubation was carried out
at 378C for 15min. The radioactive DNA product was
collected on a paper disc (DE 81, Whatman, Middlesex,
UK) and the radioactivity was measured (33).
Assayof HIV-1 RT
The reaction mixture (25ml) was comprised of 50mM
Tris–HCl (pH 8.3), 50mM KCl, 4mM MgCl2,1 mg/ml
polyU-oligo(dA)16 (10: 1), 50mM dATP, inhibitors and
HIV-1 RT (0.25 U). Incubation was performed for 20min
at 378C followed by addition of SYBR green I (125ml)
which was diluted 5000-fold with 60mM Tris, 60mM
boric acid and 1.2mM EDTA. The ﬂuorescence was
analyzed at 485nm for excitation and 535nm for emission
using a micro-plate reader (Wallac 1420 ARVOSX, Perkin
Elmer, Waltham, MA, USA). Under these reaction
conditions, the relationship between the amount of
HIV-1 RT and ﬂuorescence intensity was linear in the
range 0–0.5 U of the enzyme.
Cells and cell culture
HL60 cells were cultured in RPMI-1640 medium
(Invitrogen, Carlsbad, CA, USA) containing L-glutamine,
supplemented with 0.07mg/ml kanamycin and 10% heat-
inactivated fetal calf serum at 378C under 5% carbon
dioxide. Cultures were grown in 25cm
2 ﬂasks, 6ml per
ﬂask, in duplicate, with AZddG (in the presence of
0.005% DMSO), AZddAA or AZT added to the medium
to a ﬁnal concentration of 25 or 50mM, before culture.
Cells were counted with a hemacytometer and transferred
every four days (three to four mean population
doublings), with 0.3 10
5 cells per ﬂask seeded into
fresh medium containing analog or control medium. The
remaining cells were collected by centrifugation (800g),
washed with PBS( ) and stored at  808C until use.
DNA extraction, restriction digestion and Southern analysis
Cell pellets ( 2 10
6 cells) were suspended in 50mlo f
TE buﬀer [10mM Tris–HCl (pH 8.0), 1mM EDTA],
mixed with 0.5ml of lysis buﬀer [10mM Tris–HCl
(pH 8.0), 125mM EDTA, 10% sodium dodecyl sulfate
(SDS), 20mg/ml RNase A], incubated at 378C for 1h, and
then mixed with 20mg/ml proteinase K (5ml). Incubation
was then continued at 508C overnight, followed by phenol
extraction and ethanol precipitation. Genomic DNA
( 15mg) was completely digested in 50ml of mixture
[50mM Tris–HCl (pH 7.5), 10mM MgCl2, 1mM DTT,
100mM NaCl, 0.1mg/ml bovine serum albumin and 40 U
of Hinf I] at 378C for 4h. The mixture was further treated
by adding 10% SDS (1ml) and 20mg/ml proteinase K (1ml),
then incubated at 378C for 15min. The resulting digested
DNA was treated by phenol extraction and isolated
by ethanol precipitation. Approximately 2mg of digested
DNA per lane was electrophoresed on a 1% agarose gel.
The DNA was transferred to a nylon support membrane
and then UV-cross-linked to the membrane. Hybridiza-
tion using a digoxigenin-labeled telomere DNA probe,
and detection of telomere DNA by treatment with
AttoPhos (Promega, Madison, WI, USA) were performed
as described previously (30).
RESULTS
Inhibitory effects of 3’-azido-2’,3’-dideoxynucleoside
5’-triphosphateson HeLa cell telomerase activity
A semi-quantitative telomerase assay based on the ‘stretch
PCR’ method was performed to investigate the inhibitory
eﬀects of several nucleoside triphosphate derivatives
on HeLa cell telomerase (34). As shown in Figure 2A-2,
7142 Nucleic Acids Research, 2007, Vol. 35, No. 21the telomerase products ampliﬁed by the stretch PCR
method were detected as a ladder consisting of bands
spaced six bases apart. The ladders were abolished
by incubation (308C, 3min) with 1mg of RNase A or
by heating (908C, 5min) (data not shown). The inhibi-
tory eﬀects of AZddGTP, AZddSGTP, AZddAATP,
AZddATP and AZTTP on human telomerase were exam-
ined (Figure 2B). Although the inhibitory eﬀects of
AZTTP and AZddATP were weak, those of the guanine
analogs AZddGTP and AZddSGTP were potent. As the
concentration of AZddGTP was increased in the presence
of 10mM dGTP, the products became shorter and their
total amount decreased (Figure 2A-2). On the other hand,
AZddGTP showed very weak or no inhibition against
replicative DNA polymerases a and d (Figure 2C).
An inhibition study also showed that AZddAATP moder-
ately inhibited telomerase activity in the presence of 10mM
dATP and each of dGTP and dTTP at 200mM, but
slightly in the presence of 10mM dGTP and each of dATP
and dTTP at 200mM (Figure 2D). As shown in Figure 2E,
AZddAATP and AZddATP showed similar inhibitory
activity against HIV-1 RT. HIV-1 RT activity is generally
assayed on the basis of incorporation of radioisotope-
labeled nucleotide substrates into DNA, as described for
the assay of DNA polymerases a and d in Materials and
Methods section. However, in the present study HIV-1 RT
activity was estimated from the amount of elongated
DNA using SYBR green I staining as a convenient assay
method. This reagent, which has recently been used
for monitoring ampliﬁed DNA in real-time PCR (35),
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Figure 2. Inhibition of human telomerase, DNA polymerases a and d, and HIV-1 RT activities by nucleotide analogs. (A-1) Relationship between
telomerase in HeLa cell extract (S-100) and amount of ampliﬁed products obtained by stretch PCR method (lanes 1–4 of A-2). Lane 1, 0 ml( 0mg);
lane 2, 1.3 ml (0.7 mg); lane 3, 2.7 ml (1.3 mg); lane 4, 4 ml( 2mg). The amount of product was determined with a ﬂuorescence image analyzer and
plotted against the amount of S-100 extract. Values on the Y-axis are presented as linear arbitrary units (LAU). A standard curve correlating the
amount of enzyme and PCR product was prepared, allowing the linearity of the reaction to be conﬁrmed in each experiment. (A-2) Telomerase
activity in the presence of various concentrations of nucleotide analogs. Telomerase activity was measured as described in Materials and Methods
section in the presence of the indicated concentrations of inhibitors, 10mM dNTP bearing a similar base moiety to the inhibitor, and two other
dNTPs (200mM each). Typical results are shown. (B) Remaining activity in the presence of AZddGTP (ﬁlled triangles), AZddSGTP (open triangles),
AZddAATP (ﬁlled circles), AZddATP (open circles) and AZTTP (open squares) are shown. Activity in the absence of inhibitor was taken as 100%.
The amount of PCR product comprising a DNA ladder in each lane, as shown in panel A-2, was quantiﬁed using a ﬂuorescence image analyzer
and the percent activity was estimated. (C) Inhibitory eﬀects of AZddGTP on calf DNA polymerase a (broken line) and human DNA polymerase d
(solid line). The remaining activity of DNA polymerase in the presence of various concentrations of AZddGTP, 20mM dGTP, 50mM dATP,
50mM dCTP and 50mM[
3H]dTTP is shown. Activity in the absence of inhibitor was taken as 100%. (D) Inﬂuence of dNTP concentration
on the inhibitory eﬀects of AZddAATP on human telomerase. Remaining activity in the presence of 10mM dATP, 200mM dGTP and 200mM dTTP
(solid line) or 200mM dATP, 10mM dGTP and 200mM dTTP (broken line) is shown. Activity without inhibitor was taken as 100%. (E) Inhibitory
eﬀects of AZddAATP (ﬁlled circles) and AZddATP (clear circles) on HIV-1 RT. The remaining activity of HIV-1 RT is shown in the presence of the
indicated concentrations of inhibitor, 50mM dATP as a dNTP substrate and 1mg poly U-oligo(dA)18 as a template–primer. Activity in the absence
of inhibitor was taken as 100%.
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U-oligo(dA), poly A-oligo(dT) and poly C-oligo(dG) as
the template–primers (data not shown).
Next, the inhibitory eﬀects of nucleotide analogs
on telomerase were analyzed using Lineweaver–Burk
plots (Figure 3). The inhibition modes of AZTTP and
AZddGTP were shown to be nearly competitive with
dTTP or dGTP, respectively. However, the inhibition
mode of AZddGTP, shown in Figure 3, was not compet-
itive in a simple manner with respect to dGTP, but rather
in a complex manner, as indicated reproducibly by the
concave curves obtained at lower concentrations of dGTP.
The inhibition mode of AZddAATP was also not simple.
On the other hand, the inhibition mode of AZddSGTP
was shown to be due to a mixed-type mechanism. The
Ki values of AZTTP, AZddGTP, AZddSGTP, AZddATP
and AZddAATP were estimated to be 15, 1.5, 9.0, 4.8 and
0.26mM, respectively, and the Km values of dTTP, dGTP
and dATP were estimated to be 7.9 1.8, 8.2 2.1 and
0.97 0.31mM, respectively.
Incorporation of analogsinto DNA
We analyzed the primer extension products synthesized by
cherry salmon telomerase in the presence of ddGTP,
araGTP, AZddSGTP or AZddGTP instead of dGTP,
and in the presence of AZddAATP instead of dATP.
The results are shown in Figure 4. These experiments were
performed using an 18-mer of (50-TTAGGG-30)3 capable
of incorporating two
32P-labeled dTMP molecules at
the initial two residues, unlabled dAMP at the third
and unlabled dGMP at the fourth position (22-mer) from
the 30-end of the primer. The primer extension experi-
ment in the presence of [a-
32P]dTTP, dATP and dGTP
(complete reaction, lane 4 in Figure 4) gave long products
of various lengths, as expected. Omission of dGTP
(control reactions, lanes 1 and 6) gave products that
migrated as 19-, 20- and 21-mer bands. Similarly, omission
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7144 Nucleic Acids Research, 2007, Vol. 35, No. 21of dATP (control reaction, lane 15) gave products that
migrated as 19- and 20-mer bands. When examined in the
presence of [a-
32P]dTTP, dATP with AZddGTP (lanes 11
and 12) or ddGTP (lanes 7 and 8) instead of dGTP gave a
distinct 22-mer product, whereas AZddSGTP (lanes 2
and 3) did not give a clear 22-mer product. This means
that AZddGTP, but not AZddSGTP, is eﬀectively utilized
by telomerase as a substrate and incorporated into the
30-terminus of the primer strand, and that chain termina-
tion is elicited. When examined in the presence of
[a-
32P]dTTP, dGTP and AZddAATP (lanes 13 and 14)
instead of dATP gave only 19- and 20-mer products,
similar to the control reaction (lane 15). In this experi-
ment, the telomerase employed was partially puriﬁed from
a crude extract of immature testes of cherry salmon by
diethylaminoethyl cellulose column chromatography and
70% ammonium sulfate fractionation, followed by dia-
lysis against buﬀer. One explanation for the faint 22-mer
bands in lanes 1, 2, 3 and 6 of Figure 4 is misincorporation
of dGMP. However, we did not investigate this issue
further.
Growth rates and telomere lengthof HL60 cellsgrown
in thepresence of AZddG, AZddAA and AZT
Cultures of HL60 cells were tested with AZddG in the
presence of 0.005% dimethylsulfoxide (DMSO) and
AZddAA (Figure 5). At the concentrations chosen,
50mM AZddAA and 50mM AZddG did not cause any
signiﬁcant change in cell growth rate for ﬁrst four days.
For each culture, every four days, cells were counted to
determine cell growth rates, and passaged quantitatively
to maintain them in logarithmic growth conditions. We
tried to detect the critical point for signiﬁcant cessation
of cell growth or cell death after telomere shortening by
treatment with AZddAA or AZddG. However, as shown
in Figure 5B and D, the lines representing the rates of
cell division were almost linear, and their slopes were not
changed after treatment with these compounds. These
results suggest that the slight growth inhibition evident
in Figure 5B and D was not due to telomere shortening.
Genomic DNAs from HL60 cells cultured with AZddG
and AZddAA were restriction digested with Hinf I,
and their telomere length distributions were determined
by Southern hybridization analysis with a digoxigenin-
labeledtelomericDNAprobe(30).Theresultsareshownin
Figure5.Lanes1–3inFigure5Aandlanes1–6inFigure5C
show the results of control experiments carried out in the
absence of nucleoside analogs. Lanes 4–8 and 9–13 in
Figure 5A show the eﬀects of 25 and 50mM AZddAA,
respectively, andlanes7–12 inFigure 5Bshow theeﬀects of
50mM AZddG. In control experiments, telomere length
showed a broad distribution ranging from  2t o 6kb
(Figure 5A) and  2t o 5kb (Figure 5C), and did not
change signiﬁcantly during all passages. However, after
60 days in the presence of AZddAA, slight telomere
shortening was detected (Figure 5A), and after 24 days in
the presence of 50mM AZddG, marked telomere short-
ening was seen in comparison with the control experiments
(Figure 5C). However, these shortened telomeres returned
to the length of telomeres in the control cells within
three weeks following removal of AZddG from the culture
medium (Figure 5C, lanes 13–18).
Telomere shortening activities of AZT and AZddG
were compared (Figure 5E). When HL60 cells were
treated, AZddG showed more potent activity than
AZT. The telomere shortening activities of these two
compounds appeared to be correlated with telomerase-
inhibitory activities of their triphosphate derivatives.
DISCUSSION
Because of the structural and mechanistic similarity
between telomerase and HIV-1 RT, it has been hypothe-
sized that known RT inhibitors may potently inhibit
human telomerase. AZT is used clinically against human
immunodeﬁciency virus type 1 (HIV-1). It can be
phosphorylated to its 50-phosphate derivative (AZTTP),
which inhibits HIV-1 RT and exerts antiviral activity.
Inhibitory activity of AZTTP on telomerase has been
reported (19,36). In order to obtain more selective
and potent inhibitors of telomerase, we investigated
the inhibitory eﬀects of purine analogs of 30-azido-20,
30-dideoxynucleotides on telomerase in the hope that
conversion of AZTTP to its guanine or adenine
counterpart might change its aﬃnity for telomerase.
It should be noted that telomerase incorporates as many
as three dGTP residues during the extension reaction
of the six residue sequence TTAGGG. We are especially
interested in the inhibitory eﬀect of a guanine counter-
part of AZT, AZddGTP, on telomerase. As shown in
Figure 2B, the guanine analogs AZddGTP and
AZddSGTP showed potent inhibitory eﬀects. On the
other hand, the thymine and adenine counterparts,
AZTTP and AZddATP, showed moderate or weak
inhibition. We previously observed similar phenomena
when comparing thymine analogs and guanine counter-
parts. Arabinofuranosylthymine 50-triphosphate
(araTTP), 20-deoxy-20-ﬂuoro-5-methylarabinofuranosyl-
uracil 50-triphosphate (FMAU-TP) and 1-[(2-hydro-
xyethoxy)methyl]thymine 50-triphosphate (acycloTTP)
showed weaker telomerase-inhibitory activity than the
corresponding guanine analogs (22).
Potent inhibitory activity of AZddGTP is not due only
to a frequent incorporation of dGMP during elongation.
A possible explanation is as follows. As shown in
Figure 2B, remaining telomerase activity in the presence
of 10mM AZddATP and 10mM dATP was estimated to
be 85%. The inhibition mode of AZddATP was shown
to be approximately competitive (Figure 3). Therefore,
under the present assay conditions, incorporation of
dGMP and dTMP by telomerase was hardly inhibited
by 10mM AZddATP because of the high concentrations
of dGTP and dTTP (200mM each). This means that one-
on-one competition by AZddATP with dATP during
the extension of six residues (TTAGGG) resulted in a
residual telomerase activity of 85%. From a statistical
viewpoint, if AZddATP can compete with dATP three
times during the extension of these six residues in
the presence of 10mM dATP, total inhibition can be calcu-
lated as (85%)
3=61%. On the other hand, with 10mM
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Figure 5. Telomere lengths and growth rates of HL60 cells grown in the presence or absence of AZddAA (A and B) and AZddG (C and D),
and comparison of telomere shortening activity of AZT and AZddG (E). DNAs from serial passages of HL60 cells grown in the presence or absence of
AZddAA (A), AZddG (C and E) and AZT (E) were digested with Hinf I, run on a 1% agarose gel, and Southern blotted with a digoxigenin-labeled
telomereDNAprobe.Lanes13–18ofFigure5Cshowthetelomere lengthsofHL60cellscultured afterremovalofAZddGfromtheculturemedium, using
cells previously treated with 50mM AZddG for 52 days. MPDs of cultures treated with 0mM nucleoside analogs [control cultures, ﬁlled circles in (B), and
(D)], 25mM [open circles in (B)] and 50mM [open triangles in (B)] AZddAA and 50mM AZddG [open circles in (D)], are plotted against days cultured.
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in the presence of 10mM dGTP (Figure 2B). Thus, the
diﬀerence in inhibition potency between AZddGTP and
AZddATP may depend not only on a high frequency
of appearance of G-residues during elongation but also
other factors such as aﬃnity for the enzyme.
Although AZddATP and AZddAATP showed similar
inhibitory activity against HIV-1 RT (Figure 2E), as
shown in Figure 2B the IC50 value of AZddAATP (8mM)
for human telomerase was ﬁve times lower than that of
AZddATP (40mM), suggesting that the two-amino group
of AZddAATP is eﬀective at increasing the telomerase
inhibitory activity. HIV-1 RT replicates the HIV-1
genome and shows both RNA- and DNA-dependent
DNA polymerase activities. However, telomerase elon-
gates only the TTAGGG repeat at the very end of
genomic DNA, and is composed of a protein subunit and
a RNA subunit that includes a template sequence for
DNA synthesis (37). Thus, the two reverse transcriptases
fulﬁll diﬀerent functions. The two-amino group of the
guanine ring is a distinctive feature in the structure
of dGTP. Telomerase also showed higher aﬃnity for
AZddAATP bearing a two-amino group in the adenine
ring than it did for AZddAA (Figure 3). Thus, telomerase
appears to be an enzyme specialized for the frequent
incorporation of the dGMP moiety.
We were also interested in the 1,6-position tautomerism
equilibration of the 2,6-diaminopurine moiety of 30-azido-
20,30-dideoxy-2-aminoadenosine (AZddAA). Therefore,
50-triphosphate (AZddAATP) was designed with the
anticipation that it would function as a competitor of
both dGTP and dATP. Contrary to our expectation,
AZddAATP behaved like a competitor of dATP only
(Figure 2D).
The Ki value of AZddGTP was estimated to be
1.5mM. This value is somewhat higher than that
of ddGTP (0.65mM), when compared with that of
araGTP (1.2mM) (31), and  5 times smaller than the
Km of dGTP (8.2 2.1mM). Human telomerase seems
to prefer AZddGTP as well as ddGTP and araGTP to
dGTP. Likewise, the Ki value of AZddSGTP was
estimated to be 9mM, similar to the Km value of dGTP
(8.2 2.1mM). In the case of AZddAATP, the Ki value
was low (0.26mM), about a quarter of the Km value
of dATP (0.97 0.31mM). Only the Km for dATP was
about eight times smaller than the Km values of dGTP
and dTTP. The Km values of dGTP and dTTP (8.2 2.1
and 7.9 1.8mM) obtained here were similar to those
(8–12mM) of telomerase from human leukemia cells and
HeLa cells (38).
As shown in Figure 4, the amounts of a 22-mer chain-
terminated product in lanes 11 and 12 in the presence of
AZddGTP were somewhat higher than those in lanes 7
and 8 in the presence of ddGTP, respectively, under
similar experimental conditions. Therefore, it is suggested
that AZddGTP can be incorporated into the primer more
eﬃciently than ddGTP.
Strahl and Blackburn demonstrated that long-term
treatment of immortalized human B- and T-cell lines
with 10mM ddG caused reproducible progressive telomere
DNA shortening. However, they also reported that ddG
did not have observable eﬀects on cell population doubl-
ing rates or morphology (19). Similarly, Gomez et al.
demonstrated progressive telomere DNA shortening
in HeLa cells upon treatment with 800mM AZT (20),
but no evidence of cellular senescence could be detected.
Interestingly, Ji et al. recently reported that cyclic
treatment of human breast cancer MCF-7 cells with
AZT suppressed telomerase, followed by suppression
of telomerase RNA, and that further treatment with
AZT accelerated both telomere loss and apoptosis (39).
They conﬁrmed that AZT-induced telomere shortening
is irreversible and cumulative.
Treatment of HL60 with 50mM AZddG for 24 days
or more caused signiﬁcant telomere DNA shortening.
Additionally, shortened telomeres began to elongate when
AZddG was removed from the culture medium
(Figure 5C). These observations indicate that the telomere
shortening in AZddG-treated cells is attributed to
AZddGTP because AZddG showed only low cytotoxicity
for cultured cells (21), and AZddGTP is a potent and
selective inhibitor for telomerase (Figure 2B and C).
Treatment of HL60 cells with both AZddAA and AZddG
caused telomeres to shorten signiﬁcantly during early
passages (up to about 40–50 days) but then stabilized
during later passages. This ﬁnding is consistent with the
previous analyses demonstrating that reduced telomerase
activity can maintain telomeres at shorter equilibrium
length (40). It appears that even reduced telomerase
activity, caused by inhibitors, is suﬃcient for telomere
maintenance when telomeres are very short.
Although the number of mean population doublings
(MPDs) of HL60 cells in control culture medium was
estimated to be  4.1 per passage that of treated cells
cultured in the presence of AZddG for 24 days or more
was estimated to be  3.6. Thus, AZddG treatment caused
a slight but steady decrease in cell growth rate during
80 days of culture. However, HL60 cells maintained for
 200 days in the presence of 50mM AZddG did not show
signiﬁcant growth cessation or cell death (data not
shown). These results suggest that AZddG alone cannot
critically shorten telomeres to a degree that would lead
to cell death (41), even though AZddG caused eﬃcient
telomere shortening in our experiments.
Among the compounds tested in this study, the
Ki value for AZddAATP was the lowest (0.26mM).
However, during inhibition, AZddAATP behaved as
a dATP analog (Figure 2D). Although the Ki value
of AZddAATP was lower than that of AZddGTP
(Ki=1.5mM), the value (0.27) of Ki, AZddAATP/Km, dATP
was slightly larger than the value (0.18) of Ki, AZddGTP/
Km, dGTP. These results suggest that the inhibitory activity
of AZddGTP is comparable to that of AZddAATP.
Furthermore, cellular deoxyribonucleotide pool levels
may also inﬂuence the inhibitory activity of nucleotide
analogs. It has been reported that the levels of dATP
and dGTP pools in HL60 cells are  15 and  8mM,
respectively (42). If AZddG and AZddAA were equally
activated to the corresponding 50-triphosphates by cellular
kinases, then the inhibitory activity of AZddAATP would
be decreased by the higher dATP pool level. Indeed,
AZddAA caused less telomere shortening (Figure 5).
Nucleic Acids Research, 2007, Vol. 35, No. 21 7147It was reported that the antitumor eﬀects of cisplatin on
proliferation of the human endometrial cancer cell line
HEC-1 are enhanced in the presence of RT inhibitors (43).
Therefore, it will be of interest to search for potent
telomerase inhibitors like AZddG, which show consider-
able promise for potentiating the activity of some
antitumor agents when combined with conventional
chemotherapeutics.
CONCLUSION
AZddGTP is a potent and selective inhibitor of human
telomerase. Displacement of the 2-H of AZddATP with
an amino group is important for its inhibitory activity on
telomerase, although this modiﬁcation did not aﬀect
its inhibitory activity towards HIV-1 RT. Treatment of
HL60 cells with AZddG resulted in more potent eﬀects
on telomere shortening than treatment with AZT. Thus,
AZddG was shown to be a useful inhibitor for reprodu-
cible preparation of telomere-shortened HL60 cells;
however, AZddG alone could not critically shorten
telomeres to a degree that would lead to cell death.
Characterization of the inhibitor-treated cells is now
underway in our laboratory.
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